* pregnant or breastfeeding women; * known allergy to ivermectin or some of the components of ivermectin tablets or placebo; * current use of home oxygen; * that require hospitalization due to covid-19 at the time of diagnosis or history of hospitalization for covid-19; * presence of mal-absorptive syndrome; * presence of any other concomitant acute infectious disease; * known history of severe liver disease, for example liver cirrhosis; * need or use of antiviral drugs at the time of admission for another viral pathology other than covid-19; * need or use of hydroxychloroquine or chloroquine; * use of ivermectin up to 7 days prior to randomization; * patients on dialysis or who have required it in the last 2 months or who plan to do it in the next 2 months; * current participation or in the last 30 days in a research study that has included the administration of a drug.

* pregnant or breastfeeding women; * known allergy to ivermectin or some of the components of ivermectin tablets or placebo; * current use of home oxygen; * that require hospitalization due to covid-19 at the time of diagnosis or history of hospitalization for covid-19; * presence of mal-absorptive syndrome; * presence of any other concomitant acute infectious disease; * known history of severe liver disease, for example liver cirrhosis; * need or use of antiviral drugs at the time of admission for another viral pathology other than covid-19; * need or use of hydroxychloroquine or chloroquine; * use of ivermectin up to 7 days prior to randomization; * patients on dialysis or who have required it in the last 2 months or who plan to do it in the next 2 months; * current participation or in the last 30 days in a research study that has included the administration of a drug.

- pregnant or breastfeeding women; - known allergy to ivermectin or some of the components of ivermectin tablets or placebo; - current use of home oxygen; - that require hospitalization due to covid-19 at the time of diagnosis or history of hospitalization for covid-19; - presence of mal-absorptive syndrome; - presence of any other concomitant acute infectious disease; - known history of severe liver disease, for example liver cirrhosis; - need or use of antiviral drugs at the time of admission for another viral pathology other than covid-19; - need or use of hydroxychloroquine or chloroquine; - use of ivermectin up to 7 days prior to randomization; - patients on dialysis or who have required it in the last 2 months or who plan to do it in the next 2 months; - current participation or in the last 30 days in a research study that has included the administration of a drug.

- pregnant or breastfeeding women; - known allergy to ivermectin or some of the components of ivermectin tablets or placebo; - current use of home oxygen; - that require hospitalization due to covid-19 at the time of diagnosis or history of hospitalization for covid-19; - presence of mal-absorptive syndrome; - presence of any other concomitant acute infectious disease; - known history of severe liver disease, for example liver cirrhosis; - need or use of antiviral drugs at the time of admission for another viral pathology other than covid-19; - need or use of hydroxychloroquine or chloroquine; - use of ivermectin up to 7 days prior to randomization; - patients on dialysis or who have required it in the last 2 months or who plan to do it in the next 2 months; - current participation or in the last 30 days in a research study that has included the administration of a drug.